Commentary Open Access
Volume 1 | Issue 1 | DOI: https://doi.org/10.33696/Pharmacol.1.004
Current Issues of Novel Drug Versus Thrombosis as Main Cause of Death
Bahram Alamdary Badlou1,*
- 1Department of Research and Development, BBAdvies and Research, 3706XA, Zeist, The Netherlands
Corresponding Author
Bahram Alamdary Badlou, bbadlou@casema.nl
Received Date: January 13, 2018
Accepted Date: January 25, 2018
Borah P, Banik BK. Diverse Therapeutic Applications of Onion. Arch Pharmacol Ther. 2019; 1(1):17-18.
Copyright: © 2019 Badlou BA. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Recommended Articles
Protein Therapeutics from Monolayer to Spheroids- A Model for Preclinical Investigations
The arrival of recombinant insulin in the pharmaceutical market paved a new direction for the clinical potential of proteins. Thus, the pharmaceutical industry underwent a paradigm shift towards proteins as therapeutic moieties. A number of recombinant protein drugs are available and many more are in pipeline to target major diseases, such as cancer, viral diseases, cardiovascular diseases and endocrine disease.
The Potential of Combination Therapies and Patient Stratification to Improve CCR2 Inhibition Therapeutics
Chemokines and their receptors are the communication mechanism used by cells of the immune system, allowing them to identify and eliminate pathogens and cancerous cells. However, it is becoming clear that chemokines and their receptors are also playing a role in tumor progression and metastasis. An example of such coopting is the CCL2-CCR2 axis.
Repurposed Anti-IL-6 Therapeutics, Another Way to Quell the Cytokine Storm in Tuberculosis
Study on ‘‘cytokine storms’’ has been braced up in infectious diseases. The pertinence of this research begins to be evident in tuberculosis as it was observed that increased levels of Interleukin-6 (IL-6) were connected with disease severity. The IL-6 blockers therapeutics approaches for tuberculosis are currently a key line of research, with many in progress clinical trials, as IL-6 has become an important factor of the immune response to tuberculosis.
Pharmacology of Berberine and Its Metabolites, Is It the Natures Ozempic or Imatinib?
Berberine, a naturally occurring alkaloid, is widely explored for several health benefits, including weight management and metabolic disorders. The major pharmacological action of berberine is reported to be by activation of AMP-activated protein kinase, while its other clinical outcomes are devoid of clear mechanism of action/s. Hence in this study a detailed pharmacology of berberine and its two major metabolites (berberrubine, and jatrorrhizine) in humans was evaluated using well established Insilco tools.
Treatment of Traumatic Brain Injury: Nanotherapeutics
Nanotechnology and regenerative nanotherapeutics enrich the renewing features and function of the diseased cells and tissue by replenishing the local environment, while inhibiting further degeneration. These featured therapeutics perform cell maintenance and promote cellular events to develop better communication between re-forming molecules of remedies and the brain.